Abstract | PURPOSE: METHODS: Patients in whom ADA treatment was initiated for JIAU were included in this retrospective analysis. Reasons for discontinuing ADA treatment in patients with primary treatment response were analysed. RESULTS: Within a group of 387 JIAU patients, 59 of 68 patients who were treated with ADA achieved a sufficient response to treatment within 6 months. Here, 39 patients (66.1 %) were still on therapy at their last follow-up visit (mean treatment duration of 38.3 months, range 12-91). In another 20 patients, ADA had been discontinued after 1 or 2 years or later, in 10 % (n = 2), 45 % (n = 9) and 45 % (n = 9) of patients, respectively (mean 30.6 months; range 10-65). Reasons for discontinuing ADA were reactivation of uveitis (n = 8, 3.93 per 100 patient-years) or arthritis (n = 4; 1.97 per 100 patient-years), or ≥2 years of complete disease inactivity (n = 3, 1.47 per 100 patient-years), adverse events (n = 4; 1.89 per 100 patient-years), or other (n = 1; 0.47 per 100 patient-years). CONCLUSIONS: The data show a good primary response to ADA in patients with refractory JIAU. Due to the increasing rate of adalimumab failure or adverse events during long-term treatment, further treatment options may be required.
|
Authors | Marc Breitbach, Christoph Tappeiner, Michael R R Böhm, Beatrix Zurek-Imhoff, Carsten Heinz, Solon Thanos, Gerd Ganser, Arnd Heiligenhaus |
Journal | Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
(Graefes Arch Clin Exp Ophthalmol)
Vol. 255
Issue 1
Pg. 171-177
(Jan 2017)
ISSN: 1435-702X [Electronic] Germany |
PMID | 27687987
(Publication Type: Journal Article)
|
Chemical References |
- Antirheumatic Agents
- Adalimumab
|
Topics |
- Adalimumab
(therapeutic use)
- Adult
- Antirheumatic Agents
(therapeutic use)
- Arthritis, Juvenile
(complications, drug therapy)
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Registries
- Retrospective Studies
- Severity of Illness Index
- Time Factors
- Treatment Outcome
- Uveitis, Anterior
(drug therapy, etiology)
- Withholding Treatment
|